Robin Gupta asked:
Thrombotargets Corp is Proud to Announce its Second Orphan Drug Designation for TT-103MH for The Treatment Of Bleeding Episodes, now in Von Willebrand Patients.
TT-103MH was granted last February an Orphan Drug Designation for the treatment of bleeding episodes in Hemophiliacs. Now, Thrombotargets Corporation’s human recombinant protein, TT-103MH, has been granted by [...]